Amyloidosis is a rare but serious disease that happens when abnormal proteins called amyloid accumulate in your organs and tissues. These proteins clump together and deposit in places where they don't belong—your heart, kidneys, liver, nervous system, or other organs. Over time, these deposits interfere with how those organs work, potentially causing organ damage or failure.
Learn About Paying Your FGUA Bill Online →
The disease exists on a spectrum. Some people have amyloidosis that progresses slowly and causes minimal symptoms for years. Others experience rapid deterioration that affects their quality of life significantly. The severity and progression depend heavily on which type of amyloidosis you have, how much protein has accumulated, and which organs are involved.
Understanding amyloidosis matters because it's often misdiagnosed or diagnosed late. People frequently visit multiple doctors before getting a correct diagnosis because symptoms overlap with other common conditions like heart disease or kidney problems. Early recognition of amyloidosis and its underlying causes can change how treatment decisions are made and may slow progression.
Amyloidosis affects somewhere between 2,000 and 3,000 people in the United States, though some experts believe the actual number may be higher because many cases go undiagnosed. It's not something you catch or inherit in a straightforward way—instead, it develops through biological processes that vary depending on the type. This is why understanding what causes amyloidosis in different people is so important.
Key takeaway: Amyloidosis is a protein-folding disease where misshapen proteins accumulate in organs and cause damage. The disease presents differently depending on its type and which organs are affected, making early understanding crucial for people who suspect they might have it or have received a diagnosis.
Amyloidosis divides into two fundamental categories based on how it develops: acquired amyloidosis (which develops during a person's lifetime) and inherited amyloidosis (which runs in families because of a genetic mutation). This distinction matters enormously because it shapes risk factors, how the disease might progress, and what options exist for management.
Free Guide to Pay by Plate Illinois Billing →
Acquired amyloidosis happens when your body starts making abnormal proteins even though your genes are functioning normally. The most common acquired form is AL amyloidosis (also called primary amyloidosis), where plasma cells in your bone marrow produce misfolded light chains—parts of antibodies that stick together incorrectly. Another acquired form is AA amyloidosis, which develops as a complication of chronic inflammatory diseases. These forms aren't inherited; they occur in people with no family history of the condition.
Inherited amyloidosis, by contrast, stems from a genetic mutation passed down through families. The most widespread inherited form is hereditary transthyretin amyloidosis (hATTR), caused by mutations in the gene that makes transthyretin protein. If one of your parents carries this mutation, there's roughly a 50% chance you inherited it. However, carrying the gene doesn't guarantee you'll develop symptoms—some people with the mutation never experience problems, while others have severe disease.
The distinction between acquired and inherited has real implications. With acquired forms, doctors focus on treating whatever underlying condition triggered the amyloidosis or controlling the abnormal protein production. With inherited forms, medical attention often centers on genetic counseling for family members, monitoring for early signs of disease, and decisions about preventive treatment options.
Key takeaway: Amyloidosis either develops spontaneously during your life (acquired) or stems from a genetic mutation you inherited (hereditary). These two categories have different causes, different family implications, and sometimes different treatment paths.
AL amyloidosis represents the most common form of amyloidosis in developed countries, accounting for roughly 50-55% of all amyloidosis cases. The "AL" stands for amyloid light chain, referring to the abnormal antibody components that accumulate. What triggers AL amyloidosis isn't entirely understood, but researchers know it involves a malfunction in plasma cells—immune cells in your bone marrow that normally produce protective antibodies.
Free Guide to Mold Removal Methods for Walls →
In AL amyloidosis, plasma cells start producing light chains that are either misfolded or produced in excessive quantities. These malformed proteins don't function properly, and instead of being cleared from your body, they clump together into amyloid fibrils. These fibrils then deposit in various organs. What makes AL amyloidosis especially challenging is that people often have no obvious reason why their plasma cells began misbehaving—it's not like a cancer where there's a clear tumor. The abnormal plasma cell population may be small and easy to miss on initial testing.
AA amyloidosis develops differently. This form occurs as a secondary effect of long-standing inflammatory conditions. Diseases that trigger chronic inflammation—including rheumatoid arthritis, tuberculosis, inflammatory bowel disease, and certain infections—can lead to AA amyloidosis. In this scenario, your body produces an acute phase protein called serum amyloid A in response to inflammation. Over years or decades, some of this protein transforms and deposits as amyloid.
Other acquired forms exist but are less common. Dialysis-related amyloidosis developed in patients undergoing long-term kidney dialysis, though better dialysis techniques have made this rarer. Light chain deposition disease and heavy chain amyloidosis occur when antibody components accumulate abnormally. These forms highlight an important point: several different biological pathways can lead to amyloidosis.
What matters from a risk perspective is that people with certain conditions or undergoing certain treatments may have elevated chances of developing acquired amyloidosis. This is why individuals with chronic inflammatory diseases, long-term kidney disease, or plasma cell disorders should be aware of amyloidosis as a possible complication.
Key takeaway: Acquired amyloidosis develops when your body produces abnormal proteins—either misfolded antibody fragments (AL type) or inflammatory proteins (AA type). These forms aren't inherited but result from your body's protein-making processes going wrong.
Hereditary transthyretin amyloidosis (hATTR) causes about 10% of all amyloidosis cases but represents the most common inherited form. The transthyretin gene provides instructions for making a transport protein that moves thyroid hormone and vitamin A through your bloodstream. Over 120 different mutations in this gene have been identified, and each one slightly alters the protein structure, making it prone to misfold and clump. If you inherit a mutated transthyretin gene from either parent, you carry the risk of developing hATTR.
How to Delete Your Fitbit Account Guide →
The pattern of inheritance for hATTR is autosomal dominant, meaning you only need one mutated copy of the gene—not two—to potentially develop the disease. Your other copy of the gene may be perfectly normal, but the mutated version is enough to trigger problems. If both your parents carry the mutation, your risk is higher still, though the disease severity depends on which specific mutation you inherited, not how many copies you have.
What makes inherited amyloidosis particularly important for families is that relatives of someone with hATTR have a substantial chance of carrying the same mutation. A person with hATTR can have this information confirmed through genetic testing, and then relatives can choose to have testing as well. Some people test positive for the mutation but never develop symptoms—this is called asymptomatic or preclinical amyloidosis. Others develop symptoms in their 40s, 50s, or later.
Other inherited forms are even rarer. Hereditary lysozyme amyloidosis and hereditary fibrinogen amyloidosis result from mutations in different genes. These forms follow the same inheritance pattern—autosomal dominant—but affect fewer families. Apolipoprotein amyloidosis and beta-2 microglobulin amyloidosis represent other genetic variants that medical professionals watch for.
The practical implication is significant: if you've been diagnosed with inherited amyloidosis, your first-degree relatives (parents, children, siblings) should know about their potential risk. Some choose genetic counseling and testing to know their status, while others prefer not to know. There's no right choice, but the information should be available so families can decide what's best for them.
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.